Literature DB >> 21975146

Omalizumab. An option in vernal keratoconjunctivitis?

J Sánchez, R Cardona.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21975146     DOI： 10.1016/j.aller.2011.08.002

Source DB:  PubMed          Journal:  Allergol Immunopathol (Madr)        ISSN： 0301-0546            Impact factor:   1.667


× No keyword cloud information.
  5 in total

Review 1.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 2.  Emerging Therapeutics for Ocular Surface Disease.

Authors:  Leonard Bielory; Dovid Schoenberg
Journal:  Curr Allergy Asthma Rep       Date:  2019-02-28       Impact factor: 4.806

Review 3.  An Overview of Off-Label Use of Humanized Monoclonal Antibodies in Paediatrics.

Authors:  Roberto Bernardini; Gaia Toschi Vespasiani; Arianna Giannetti
Journal:  Medicina (Kaunas)       Date:  2022-04-29       Impact factor: 2.948

4.  Omalizumab in Severe Refractory Vernal Keratoconjunctivitis in Children: Case Series and Review of the Literature.

Authors:  Serge Doan; Flore Amat; Eric Gabison; Sarah Saf; Isabelle Cochereau; Jocelyne Just
Journal:  Ophthalmol Ther       Date:  2016-12-01

Review 5.  Pediatric usage of Omalizumab: A promising one.

Authors:  Lin Yu; Huishan Zhang; Jianwei Pan; Leping Ye
Journal:  World Allergy Organ J       Date:  2021-12-11       Impact factor: 4.084
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.